Vaccination therapy combined with chemotherapy for recurrent pancreatic cancer patients

点击翻译按钮获取中文摘要

A phase I trial of vaccination therapy using dendrite cells pulsed with HSP105 peptide was conducted. Inclusion criteria were patients with advanced/recurrent cancer with cancer tissue expressing HSP105 and with HLA-A2 or HLA-A24. Dosing-up protocols were applied using 5x106 DC cells/tretament (step 1), 1X107 DC cells/treatment (step 2), and 2X107 DC cells/ treatment (step 3).In the step 1, CD8 positive T cells specific for HSP105 were not recognized. In the step 2, DTH reaction was found in all the patients. Tumor response was SD in 1, and PD in 2. In the step 3, 4 patients with pancreatic cancer were the candidates, but only one patient received the therapy, as PS deteriorated in the other 3 patients. DTH reaction was also be found, but the tumor response was PD.